ArticleEFSA journal. European Food Safety Authority2020
Rift Valley Fever - epidemiological update and risk of introduction into Europe.
Article in EFSA journal. European Food Safety Authority, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- Mechanistic models of Rift Valley fever virus transmission: A systematic review.PLoS neglected tropical diseases · 2022Pooled it
- Paving the way for human vaccination against Rift Valley fever virus: A systematic literature review of RVFV epidemiology from 1999 to 2021.PLoS neglected tropical diseases · 2022Pooled it
- Rift Valley Fever at Europe's Risk Frontier: Climate, Vectors, and One Health Preparedness.Veterinary sciences · 2026Review
- Simulating the Transmission of Rift Valley Fever Virus via Raw Milk Consumption in Inter-Epidemic Periods.Viruses · 2026Article
- Mosquito viromes across England and Wales reveal hidden arbovirus signals and limited ecological structuring.Frontiers in microbiology · 2026Article
- [Risk of emergence of mosquito-borne arboviral diseases in Morocco: literature review].Medecine tropicale et sante internationale · 2025Review
- Infectious disease risk after the October 2024 flash flood in Valencia, Spain: Disaster evolution, strategic scenario analysis, and extrapolative baseline for a One Health assessment.One health (Amsterdam, Netherlands) · 2025Article
- Incidence rate of Rift Valley fever exposure in humans and livestock from a longitudinal study in Northern Kenya.Scientific reports · 2025Article
- Recent advances in treatment and detection of Rift Valley fever virus: a comprehensive overview.Virus genes · 2025Review
- Inter-epidemic seroprevalence of Rift Valley fever virus and associated risk factors in humans in Eastern Rwanda.PLoS neglected tropical diseases · 2025Article
- The public health threat of emerging phenuiviruses.One health (Amsterdam, Netherlands) · 2025Review
- Transmission of autochthonous Aedes-borne arboviruses and related public health challenges in Europe 2007-2023: a systematic review and secondary analysis.The Lancet regional health. Europe · 2025Article
- Introduction of Vector-Borne Infections in Europe: Emerging and Re-Emerging Viral Pathogens with Potential Impact on One Health.Pathogens (Basel, Switzerland) · 2025Review
- Revisiting the risk of introduction of Japanese encephalitis virus (JEV) into the United States - An updated semi-quantitative risk assessment.One health (Amsterdam, Netherlands) · 2024Article
- Distribution and abundance of Aedes caspius (Pallas, 1771) and Aedes vexans (Meigen, 1830) in the Po Plain (northern Italy).Parasites & vectors · 2024Article
- Tissue distribution and transmission of Rift Valley fever phlebovirus in EuropeanThe Journal of general virology · 2024Article
- The socioeconomic impacts of Rift Valley fever: A rapid review.PLoS neglected tropical diseases · 2024Review
- Genomic Epidemiology of Rift Valley Fever Virus Involved in the 2018 and 2022 Outbreaks in Livestock in Rwanda.Viruses · 2024Article
- Evaluation of commercial ELISA kits' diagnostic specificity for FAST diseases in wild animals.The Onderstepoort journal of veterinary research · 2024Article
- Rift Valley Fever Virus: An Overview of the Current Status of Diagnostics.Biomedicines · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rift Valley fever (RVF) is a vector-borne disease transmitted by a broad spectrum of mosquito species, especially Aedes and Culex genus, to animals (domestic and wild ruminants and camels) and humans. Rift Valley fever is endemic in sub-Saharan Africa and in the Arabian Peninsula, with periodic epidemics characterised by 5-15 years of inter-epizootic periods. In the last two decades, RVF was notified in new African regions (e.g. Sahel), RVF epidemics occurred more frequently and low-level enzootic virus circulation has been demonstrated in livestock in various areas. Recent outbreaks in a French overseas department and some seropositive cases detected in Turkey, Tunisia and Libya raised the attention of the EU for a possible incursion into neighbouring countries. The movement of live animals is the most important pathway for RVF spread from the African endemic areas to North Africa and the Middle East. The movement of infected animals and infected vectors when shipped by flights, containers or road transport is considered as other plausible pathways of introduction into Europe. The overall risk of introduction of RVF into EU through the movement of infected animals is very low in all the EU regions and in all MSs (less than one epidemic every 500 years), given the strict EU animal import policy. The same level of risk of introduction in all the EU regions was estimated also considering the movement of infected vectors, with the highest level for Belgium, Greece, Malta, the Netherlands (one epidemic every 228-700 years), mainly linked to the number of connections by air and sea transports with African RVF infected countries. Although the EU territory does not seem to be directly exposed to an imminent risk of RVFV introduction, the risk of further spread into countries neighbouring the EU and the risks of possible introduction of infected vectors, suggest that EU authorities need to strengthen their surveillance and response capacities, as well as the collaboration with North African and Middle Eastern countries.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.